Confusion reigns.
Gilead Sciences treated 397 severely ill coronavirus patients with its Ebola antiviral REMDESIVIR. Regardless of whether they were treated for five or 10 days, more than half of the patients were discharged from the hospital within 14 days. After the announcement Gilead's stocks were halted ahead of trading on the NYSE
Leaked data from the WHO suggested last week that the drug had 'failed'.
Market shenanigans or a break through ?
Edit:
From a quick google search:
Gilead is now testing the drug in a further 5,600 patients at 180 locations for the next stage including in the US, the UK, China, France, Germany, Hong Kong, Italy, Japan Korea, the Netherlands, Singapore, Spain, Sweden, Switzerland, and Taiwan. The company expects to report results on the first 600 patients involved by the end of May.
So, none the wiser ... yet.